培美曲塞联合奈达铂治疗晚期肺腺癌的临床观察

目的：评价培美曲塞联合奈达铂治疗晚期肺腺癌的疗效及不良反应。方法：入组32例经病理确诊的晚期肺腺癌患者，给予培美曲塞500mg/m^2静滴，第1天；奈达铂80mg/m2静滴，第1天，3周为1个周期，2个周期后评价疗效及不良反应。结果：32例患者中完全缓解（CR）0例，部分缓解（PR）9例，稳定（SD）15例，进展（PD）8例。有效率 RR （CR＋ PR）28．1％。中位生存期11．8个月，1年存活率46．9％。结论：培美曲塞联合奈达铂治疗晚期肺腺癌具有较好的疗效及安全性。

Clinical Observation of Pemetrexed Combined Nedaplat in the Treatment of Patients with Advanced Lung Adenocarcinoma

Objective：To observe the therapeutic effect and toxicity of Pemetrexed combined Nedaplat in the treatment of patients with advanced lung adenocarcinoma. Methods： The 32 patients with pathologically confirmed lung adenocar- cinoma were treated with Pemetrexed 500mg/m^2 and Nedaplat 80mg/m^2 , dl, ivdrip, the schedule was repeated every 3 weeks and were evaluated effect after 2 cycles. Results： No patients had complete response（CR）, 9 patients had partial response（PR）, 15 patients had SD, 8 patients had PD, RR（CR＋PR）28. 1 % （9/32）. The median survival time was 11.8 months. The 1-year survival rate was 46. 9 %. Condusion：The pemetrexed combined nedaplat is effective and safe in the treatment of advanced lung adenocarcinoma patients.